ClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
February 18, 2021 16:35 ET | Source: ClearPoint Neuro, Inc. ClearPoint Neuro, Inc. Irvine, California, UNITED STATES
IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the commencement of a proposed underwritten public offering of its shares of common stock. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips
ClearPoint Neuro, Inc.February 18, 2021 GMT
Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™’ Brain Model by 2022
IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a worldwide license and research agreement with Philips, a global leader in health technology, to commercialize the ClearPoint ‘Maestro’ Brain Model. The company expects the first-generation anatomical segment analysis tool to be launched in 2022.
(1)
IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoint s Biologics and Drug Delivery team on March 1, 2021. Dr. Salegio brings over 19 years of experience in translational neuroscience with direct pre-clinical central nervous system (CNS) expertise in the delivery of therapeutics to the brain and spinal cord, including over 16 years of gene therapy experience working with adeno-associated viral vectors (AAV).
ClearPoint Neuro s Biologics and Drug Delivery team was established in 2020 to provide turn-key medical device innovation, therapy delivery development and clinical services customized for both pharmaceutical and academic partners working on gene and stem cell therapies to the brain. This tea
ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint 2.0 Software in Europe
IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the first utilization in Europe of its Version 2.0 software, together with the ClearPoint Neuro Navigation System, at Rigshospitalet in Copenhagen, Denmark. The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain. ClearPoint offers a stereotactic system based on MRI localization with an MRI compatible frame. My clear impression, after my first-time experience, is that the system offers superior accuracy of the stereotactic procedure as compared to our standard frame with CT localization, stated Rune Rasmussen, MD, PhD, Head of Stereotactics at Rigshospitalet. With a sma